SBSébastien Bihorel

Sébastien Bihorel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sébastien Bihorel has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reply to “Aflibercept 8 mg: From Ocular Clearance to Pharmacodynamic Duration”

    by Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, Thomas Eissing, Kenneth C. Turner, Joachim Höchel, Zhongqing Will He, John D. Davis, Lutz O. Harnisch

  • Open Access

    Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products

    by Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, Thomas Eissing, Kenneth C. Turner, Joachim Höchel, Torsten Zimmermann, Zhongqing Will He, John D. Davis, A. Thomas DiCioccio, et al.

    Neovascular age‐related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial vision loss. The 2‐mg drug product of aflibercept (AFL‐2)—an anti‐vascular endothelial growth factor agent—has established efficacy and safety in both diseases. In pivotal trials, a high‐dose drug product (AFL‐HD) using a formulation distinct from AFL‐2 and delivering 8‐mg aflibercept every 12 or 16 weeks (following initial monthly dosing) provided visual gains non‐inferior to AFL‐2 administered every 8 weeks (following initial monthly dosing) and comparable safety with fewer injections over 96 weeks. Free and bound aflibercept concentrations in plasma from 2744 participants in 16 clinical trials where aflibercept was administered intravitreally, subcutaneously, or intravenously were analyzed by population pharmacokinetic modeling. A semi‐mechanistic model described the release of free aflibercept from the eye and its target‐mediated elimination from plasma. The evaluated covariates (weight, age, sex, albumin, disease, racial classification, Japanese origin, renal and hepatic functions) resulted in only small numerical differences in systemic exposure. Ocular clearance ( Q E ; characterizing the bidirectional transfer of free aflibercept between the eye and central compartment) was comparable across both diseases after adjusting for an age‐dependent decrease. The change in drug product, and not just the dose increase, was responsible for a 39.4% slower Q E and extended exposure in the ocular space for AFL‐HD versus AFL‐2. The median ocular concentrations of free aflibercept predicted at the end of the 8‐week dosing interval for AFL‐2 were typically reached 14 weeks after AFL‐HD injections, versus 9–9.5 weeks if Q E was identical for both drug products.


  • Open Access

    Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia

    by Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Yuhuan Wang, Poulabi Banerjee, Robert Pordy, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch

    Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH). A population pharmacokinetic (PK)/pharmacodynamic (PD) model was previously developed to characterize evinacumab exposure and LDL‐C response in adolescents and adults. In this analysis, the PK/PD model was refined to include children aged 5 to < 12 years and to characterize the lipoprotein apheresis effect on LDL‐C reduction. The PK of evinacumab was characterized by a two‐compartment model with parallel linear and non‐linear elimination. Linear disposition parameters were allometrically scaled by body weight. Baseline ANGPTL3 concentrations and disease status (non‐HoFH vs. HoFH) influenced the maximum target‐mediated rate of elimination but had a minimal effect on evinacumab exposures at 15 mg/kg intravenous doses every 4 weeks across weight/age groups. In patients with HoFH, the LDL‐C reduction was adequately described by an indirect response model in which evinacumab inhibits the formation of LDL‐C and that includes a secondary elimination process quantifying the lipoprotein apheresis effect. Older age was associated with a decrease in baseline LDL‐C. An increase in body weight was associated with a reduction in the maximum inhibitory effect of evinacumab. Model‐based simulations showed that while evinacumab exposure is reduced with decreasing age/body weight, younger patients are predicted to have a comparable or greater magnitude of LDL‐C reduction than older patients at a dose of 15 mg/kg. Overall, the model adequately predicted the evinacumab exposure and LDL‐C reduction in children, adolescents, and adults with HoFH, aligning with clinically relevant observations.


  • Open Access

    Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia

    by Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Katy C. Norman, Richard T. George, Xue‐Qiao Zhao, Robert Pordy, Daniel Garcia, Wendy S. Putnam, Geetha Raghuveer, et al.

    Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH. Population pharmacometric models characterizing evinacumab exposure and LDL‐C response accounting for lipoprotein apheresis effect in ≥ 5‐year‐old patients were adapted for growth and maturation to predict and compare evinacumab and LDL‐C concentrations across age/weight groups in virtual ≥ 6‐month‐old patients receiving 15 mg/kg evinacumab intravenous (iv) infusions every 4 weeks (q4w). As expected from allometric theory, weight‐based dosing resulted in decreasing evinacumab exposures with declining body weight. Consistent with trends observed in > 5‐year‐old patients, the predicted percent change from LDL‐C baseline (%∆LDL‐C) was generally comparable or even higher in < 5‐year‐old patients (63.0%–68.5%) than in 5‐ to < 18‐year‐old patients (61.3%–67.8%) or adults (51.7%), with the predicted percentages of patients achieving %∆LDL‐C > 50% also higher in < 5‐year‐old patients (82.0%–86.9%) versus 5‐ to < 18‐year‐old patients (72.0%–84.5%) and adults (54.8%). Through a managed access program, six 1‐ to < 5‐year‐old patients received between 5 and 23 iv infusions of 15 mg/kg evinacumab q4w. Rapid and clinically meaningful LDL‐C reductions were observed, with %∆LDL‐C at the last reported dose ranging from 41.3% to 77.3%. Based on the actual patient dosing and plasmapheresis history, model‐predicted evinacumab and LDL‐C concentrations were comparable to the observed data collected in the managed access program. Overall, this analysis provides evidence for the use of evinacumab 15 mg/kg iv q4w dosing regimen in 6‐month‐old to 5‐year‐old patients.


  • Open Access

    Population Pharmacokinetic/Pharmacodynamic and Exposure‐Response Modeling Analyses of Sotatercept in Healthy Participants and Patients with Pulmonary Arterial Hypertension

    by Sihem Ait‐Oudhia, David Jaworowicz, Ziheng Hu, Mitali Gaurav, Heather Barcomb, Shuai Hu, Sébastien Bihorel, Budda Balasubrahmanyam, Bipin Mistry, Janethe de Oliveira Pena, et al.

    Sotatercept is a breakthrough, first‐in‐class biologic, recently approved by the Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH). Exposure‐response (E‐R) analyses and pharmacokinetic/pharmacodynamic (PK/PD) modeling were performed for sotatercept after intravenous and subcutaneous (SC) administrations. Clinical endpoints included 6‐minute walk distance (6MWD), pulmonary vascular resistance (PVR), and probability of N‐terminal pro‐B natriuretic peptide (NT‐proBNP) concentrations < 300 pg/mL for efficacy, and hemoglobin (Hgb) for safety from two Phase 1 studies, two Phase 2 studies, and one Phase 3 study. E‐R models using nonlinear mixed effect modeling approach were developed for 6MWD and PVR, while Cox proportional hazards model and semi‐mechanistic PK/PD model were used for NT‐proBNP and Hgb. Covariate analyses were conducted to identify significant predictors of variability for each of these clinical endpoints. Modeling results showed that increasing sotatercept average concentration (Cavg) at week 24 is associated with increased predicted 6MWD, increased probability of NT‐proBNP concentration < 300 pg/mL, decreased predicted PVR, and increased Hgb which was clinically manageable. All these responses approached their corresponding plateaus at a Cavg range associated with the dose of 0.7 mg/kg Q3W SC. Statistically relevant covariates included age and iron supplementation which slightly increased Hgb‐mediated effect for 6MWD, PAH disease duration, and baseline therapy infusion with prostacyclin for PVR, and WHO functional class for NT‐proBNP. The magnitudes of the impact of these covariates are not clinically meaningful. Taken together, these results support an appropriate benefit–risk profile for the FDA‐approved target dose for sotatercept of 0.7 mg/kg Q3W SC.


  • Open Access

    Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension

    by Sihem Ait‐Oudhia, David Jaworowicz, Ziheng Hu, Sébastien Bihorel, Shuai Hu, Budda Balasubrahmanyam, Bipin Mistry, Janethe de Oliveira Pena, Larissa Wenning, Ferdous Gheyas

    Sotatercept is a breakthrough, first‐in‐class biologic, that is FDA‐approved for the treatment of pulmonary arterial hypertension (PAH). A population pharmacokinetic (PopPK) model was developed using data from two phase 1 studies in healthy participants, and two phase 2 studies and one phase 3 study in participants with PAH. The pooled sotatercept PK data encompassed single intravenous (IV) or subcutaneous (SC) doses ranging from 0.01 to 3.0 mg/kg, as well as multiple SC doses ranging from 0.03 to 1.0 mg/kg, with PK samples collected up to a maximum of ~150 weeks following Q3W and Q4W dosing regimens. The final PopPK analysis included 350 participants, with 30 and 320 participants receiving sotatercept IV and SC, respectively. A two‐compartment model with a first‐order absorption rate constant and a linear disposition from central compartment well‐described sotatercept PK. The estimated bioavailability is ~66%; bioavailability, clearance (CL), and central volume (VC) have low to moderate inter‐individual variability. Time‐varying body weight and baseline albumin concentration were statistically significant predictors of PK; CL and VC were predicted to increase with increasing body weight, while CL was predicted to decrease with increasing baseline albumin concentration. However, the magnitude of covariate effects is not predicted to meaningfully alter the disposition of sotatercept. Altogether, the PopPK modeling results demonstrate favorable PK characteristics (low to moderate variability and typical bioavailability), supporting sotatercept as a SC biological agent for the treatment of patients with PAH.


  • Top Cited Papers
    Open Access

    Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia

    by Albert Wiegman, Susanne Greber-Platzer, Shazia Ali, M. Doortje Reijman, Eliot A Brinton, Min-Ji Charng, Shubha Srinivasan, Carissa Baker-Smith, Seth Baum, Julie A. Brothers, et al.

    BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels due to profoundly defective LDL receptor (LDLR) function. Given that severely elevated LDL-C starts in utero, atherosclerosis often presents during childhood or adolescence, creating a largely unmet need for aggressive LDLR-independent lipid-lowering therapies in young patients with HoFH. Here we present the first evaluation of the efficacy and safety of evinacumab, a novel LDLR-independent lipid-lowering therapy, in pediatric patients with HoFH from parts A and B of a 3-part study. METHODS: The phase 3, part B, open-label study treated 14 patients 5 to 11 years of age with genetically proven HoFH (true homozygotes and compound heterozygotes) with LDL-C >130 mg/dL, despite optimized lipid-lowering therapy (including LDLR-independent apheresis and lomitapide), with intravenous evinacumab 15 mg/kg every 4 weeks. RESULTS: Evinacumab treatment rapidly and durably (through week 24) decreased LDL-C with profound reduction in the first week, with a mean (SE) LDL-C reduction of −48.3% (10.4%) from baseline to week 24. ApoB (mean [SE], –41.3% [9.0%]), non–high-density lipoprotein cholesterol (–48.9% [9.8%]), and total cholesterol (–49.1% [8.1%]) were similarly decreased. Treatment-emergent adverse events were reported in 10 (71.4%) patients; however, only 2 (14.3%) reported events that were considered to be treatment-related (nausea and abdominal pain). One serious treatment-emergent adverse event of tonsillitis occurred (n=1), but this was not considered treatment-related. CONCLUSIONS: Evinacumab constitutes a new treatment for pediatric patients with HoFH and inadequately controlled LDL-C despite optimized lipid-lowering therapy, lowering LDL-C levels by nearly half in these extremely high-risk and difficult-to-treat individuals. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04233918.